Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): Cancer concerns

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 9, 2005, Pages 1179-1180

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; BURNING SENSATION; CANCER; CANCER RISK; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECZEMA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MELANOMA; NONHUMAN; PRURITUS; RESPIRATORY TRACT INFECTION; SARCOMA; SHORT SURVEY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY;

EID: 17844373260     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.050373     Document Type: Short Survey

References (3)

1. US Food and Drug Administration. FDA Public Health Advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. 2005 Mar 10. Available at: www.fda.gov/medwatch/SAFETY/2005/safety05 .htm#Elidel (accessed 2005 Mar 30).
2. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005;330:516-22.
3. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960-7.